These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 10155294

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A less costly regimen of alglucerase to treat Gaucher's disease.
    Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, Gelbart T, Beutler E.
    N Engl J Med; 1992 Dec 03; 327(23):1632-6. PubMed ID: 1435900
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Individualised low-dose alglucerase therapy for type 1 Gaucher's disease.
    Hollak CE, Aerts JM, Goudsmit R, Phoa SS, Ek M, van Weely S, von dem Borne AE, van Oers MH.
    Lancet; 1995 Jun 10; 345(8963):1474-8. PubMed ID: 7769902
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.
    Connock M, Burls A, Frew E, Fry-Smith A, Juarez-Garcia A, McCabe C, Wailoo A, Abrams K, Cooper N, Sutton A, O'Hagan A, Moore D.
    Health Technol Assess; 2006 Jul 10; 10(24):iii-iv, ix-136. PubMed ID: 16796930
    [Abstract] [Full Text] [Related]

  • 7. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL, Figgitt DP.
    Pharmacoeconomics; 2004 Jul 10; 22(6):389-411. PubMed ID: 15099124
    [Abstract] [Full Text] [Related]

  • 8. Enzyme replacement therapy for Gaucher's disease.
    Beutler E.
    Baillieres Clin Haematol; 1997 Dec 10; 10(4):751-63. PubMed ID: 9497862
    [Abstract] [Full Text] [Related]

  • 9. Alglucerase for Gaucher's disease: dose, costs and benefits.
    Beutler E, Garber AM.
    Pharmacoeconomics; 1994 Jun 10; 5(6):453-9. PubMed ID: 10147261
    [No Abstract] [Full Text] [Related]

  • 10. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C, vom Dahl S, Häussinger D.
    Eur J Med Res; 1998 Feb 21; 3(1-2):25-30. PubMed ID: 9512964
    [Abstract] [Full Text] [Related]

  • 11. Alglucerase: the debate continues.
    Push S.
    Pharmacoeconomics; 1995 Mar 21; 7(3):268-9. PubMed ID: 10155316
    [No Abstract] [Full Text] [Related]

  • 12. [Alglucerase treatment of type I Gaucher's disease. Preliminary results in Spain. Spanish Group on Gaucher's Disease].
    Pérez-Calvo JI, Giraldo P, Giralt M.
    Sangre (Barc); 1997 Jun 21; 42(3):189-94. PubMed ID: 9381260
    [Abstract] [Full Text] [Related]

  • 13. Budget Impact Analysis of Eliglustat for the Treatment of Gaucher Disease Type 1 in the United States.
    Nalysnyk L, Sugarman R, Cele C, Uyei J, Ward A.
    J Manag Care Spec Pharm; 2018 Oct 21; 24(10):1002-1008. PubMed ID: 30247105
    [Abstract] [Full Text] [Related]

  • 14. [Enzyme replacement therapy: a new treatment concept in Gaucher disease].
    Beck M, Mengel E, Barone R.
    Wien Klin Wochenschr; 1997 Feb 14; 109(3):81-5. PubMed ID: 9139464
    [Abstract] [Full Text] [Related]

  • 15. Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1.
    Pérez-Calvo J, Giraldo P, Pastores GM, Fernández-Galán M, Martín-Nuñez G, Pocoví M.
    J Postgrad Med; 2003 Feb 14; 49(2):127-31. PubMed ID: 12867687
    [Abstract] [Full Text] [Related]

  • 16. Managing public payment for high-cost, high-benefit treatment: enzyme replacement therapy for Gaucher's disease in Ontario.
    Clarke JT, Amato D, Deber RB.
    CMAJ; 2001 Sep 04; 165(5):595-6. PubMed ID: 11563212
    [No Abstract] [Full Text] [Related]

  • 17. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience.
    MacKenzie JJ, Amato D, Clarke JT.
    CMAJ; 1998 Nov 17; 159(10):1273-8. PubMed ID: 9861225
    [Abstract] [Full Text] [Related]

  • 18. Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment.
    Zimran A, Elstein D, Kannai R, Zevin S, Hadas-Halpern I, Levy-Lahad E, Cohen Y, Horowitz M, Abrahamov A.
    Am J Med; 1994 Jul 17; 97(1):3-13. PubMed ID: 8030654
    [Abstract] [Full Text] [Related]

  • 19. [Gaucher disease type 1--therapeutic results of enzyme substitution].
    Steensberg J, Nielsen KG, Brandt NJ.
    Ugeskr Laeger; 1998 Jun 22; 160(26):3929-30. PubMed ID: 9656836
    [Abstract] [Full Text] [Related]

  • 20. Gaucher's disease in pregnancy.
    Rosnes JS, Sharkey MF, Veille JC, Mueller-Heubach E.
    Obstet Gynecol Surv; 1996 Sep 22; 51(9):549-58. PubMed ID: 8873155
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.